Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Serina Therapeutics to Present at the 38th Annual Roth Conference
Stock Market Today: S&P 500, Dow Futures Down Ahead Of 'Triple Witching' As Iran Warns Of 'Zero Restraint'—FedEx, Super Micro Computer In Focus
Serina Therapeutics (SER) Stock Surges Over 39% After Hours— Here's Why
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event
What Sparked Serina Therapeutics (SER) 35% After-Hours Surge?
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease
Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity
Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
Serina Therapeutics Provides Regulatory Update on SER-252 Program
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors
Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease
Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway
Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
SER Launches AI-Powered Purchase-to-Pay and Order-to-Cash Solution Bundles to Boost SAP Productivity
Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough
Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)
Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference
Serina Therapeutics Makes Grant to New Employee Under Inducement Plan
Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting
Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025
UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42
Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
Serina Therapeutics to Present at JonesResearch Virtual CNS Day
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease